Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $25
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jason Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $18 to $25.
Citizens analyst Jason Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $18 to $25.